A federal judge in California is set to decide whether to dismiss 21 products liability lawsuits filed against Medtronic Inc. alleging off-label use of its Infuse bone-graft device.

Infuse, a bioengineered bone-growth protein used in spinal surgeries, has spawned at least 750 lawsuits and potentially 2,600 additional unfiled claims against Medtronic, according to the company’s June 20 annual report.